Health
Immune checkpoint inhibitor efficacy against glioblastoma may decrease with dexamethasone – Medical Xpress
Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had…
Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
“Dexamethasone is a potent corticosteroid that is often prescribed to patients with glioblastoma to treat symptoms related to cerebral edema, or swelling in the brain,” said…
-
General8 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Business16 hours agoBell Potter names the best ASX shares to buy in October
-
Noosa News15 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
General13 hours agoAustralia welcomes Gaza peace progress, hostage release